Merck Raises 2026 Guidance Again
German drugmaker Merck KGaA raised its full-year 2026 core profit guidance for the third time this year, driven by strong underlying performance and acquisitions. The company now expects adjusted EBITDA between €6.2 billion and €6.4 billion.
Xurve View
Insights:
Xurve View
Merck KGaA raised its 2026 core profit guidance to a range of €6.2B to €6.4B on Thursday morning, driven by strong underlying performance. The Germany headquartered drugmaker upgraded its outlook for the third time this year. The revision reflects improving foreign exchange effects and contributions from recent portfolio expansion.
